💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Medico Remedies Limited is an India-based company, principally engaged in the pharmaceutical business. The Company is involved in the development, manufacture and sale of pharmaceutical and nutraceutical products. It focuses on anti-infective, Beta-Lactams, cephalosporins,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
An exceptional, fast-growing business, trading cheap versus its own history.
Medico Remedies is scored on the pharma / healthcare framework. It keeps a slim 6.2% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.45×) — worth a closer look. Free cash flow is worth about 0.9% of its market value.
Over the last 3 years revenue compounded at 14%/yr and profit at 22%/yr. Book value itself has compounded 20%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 17.4%. In the latest quarter profit fell 57% versus the prior quarter.
At 11× earnings, the stock sits at the 1st percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price asks for only ~1%/yr growth over a decade — undemanding expectations. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 10.86 | — | — |
| P/B | 1.98 | 4.1 | better |
| EV/EBITDA | 7.11 | 19.33 | better |
| ROE | 17.38 | — | — |
| ROCE | 20.98 | 14.41 | better |
| ROA | 9.01 | 1.64 | better |
| Quick Ratio | 1.27 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 14% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (22% vs 14%) — margin expansion is at work. The latest year saw a +30% swing — check if it's a one-off or structural.
Operating margin has expanded from 7% to 9% — the business is keeping more of each rupee earned.
ROE at 17% — a respectable return on shareholder capital. High ROE despite single-digit margins — an asset-turn play with high capital velocity. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 22% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 0.4× PAT — reported profit isn't translating into cash, raising earnings quality questions. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 18% sequentially — momentum is building. Run-rate stepping up — recent quarters average 15% above earlier ones.
Profit fell 57% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 61.4% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.